| INTRODUC TI ON
Deletion of 20q is a recurrent cytogenetic abnormality seen in a broad spectrum of hematologic malignancies. Del(20q) is observed in 5%-7% of myelodysplastic syndrome (MDS), 1%-2% of acute myeloid leukemia (AML), and 10% of myeloproliferative disease. [1] [2] [3] Although frequently observed in myeloid neoplasm, del(20q) is insufficient as definitive evidence for diagnosis of myeloid neoplasm. 4 Del(20q) has been suggested as an age-related clonal hematopoiesis (ARCH), 5 in that it was the most frequently detected large structural genetic mosaicism alteration in a healthy aging population. 6 Moreover, the prevalence of 20q deletion was more common than that of myeloid neoplasm. 7 ARCH-related copy number variation (CNV) predicted an increased risk of hematologic malignancy, 8, 9 but the clinical significance of hematopoietic stem cell transplantation (HSCT) from a donor with such clonal hematopoiesis remains uncertain.
Herein, we report the clonal dominance of a donor-derived del(20q) clone after allogeneic HSCT in an AML patient with known 
| MATERIAL AND ME THODS
Conventional cytogenetics and fluorescence in situ hybridization (FISH).
Conventional karyotyping was analyzed in 24 hours without mitotic stimulation bone marrow (BM) aspirate samples. G-banding was achieved using trypsin-Wright staining, and the banded meta- 
| RE SULTS
A 57-year-old male was referred for general weakness and pancy- 
| D ISCUSS I ON
Del(20q), along with other hematological malignancy-associated CNVs such as 5q, 11q, and 17p, has been identified in 2% of healthy individuals older than 70 years. Such clonal hematopoiesis is an age-related condition and predicts increased risk of hematologic malignancy. 8, 9 Since del(20q) is asymptomatic, donor stem cells harboring The patients who acquired isolated del(20q) after cytotoxic therapy had innocuous BM finding in more than 77% of patients. 11, 12 Moreover, would the abnormal clone react equivalently in our patient as in the donor? The interplay of BM microenvironment and leukemia cells has been suggested, 13 and there is a chance that the del(20q) clone will progress to myeloid neoplasm in the BM microenvironment of someone previously diagnosed with AML harboring the same cytogenetic abnormality.
As del(20q) has been suggested as an ARCH, we presumed that donor-derived del(20q) will share some features of donor-derived clonal hematopoiesis of indeterminate potential (CHIP). The impact of donor-derived CHIP in HSCT recipients is controversial. Among patients with impaired hematopoietic recovery after HSCT, CHIP was commonly found, and a strong association between unexplained cytopenia and HSCT from donors with CHIP has been suggested. 14 Another recent study reviewed recipients allografted with donor CHIP and found a lower cumulative incidence of relapse/progression and no effect on overall survival despite the increased risk of donor cell leukemia. 15 The impact of CHIP in overall survival did not vary between the underlying hematologic malignancies that led to HSCT, except myeloproliferative neoplasm. Both studies have shown that donor cell leukemia due to donor-engrafted CHIP is a relatively rare complication. 14, 15 Although few cases are present to confer the role of donor-engrafted del(20q), all such (2/2) cases showed expansion of del (20q) F I G U R E 2 Fluorescence in situ hybridization analysis using a D20S108/20qter probe (XL D20S108 SpectrumOrange/20qter SpectrumGreen Probe, MetaSystems, Altlussheim, Germany). A, A single D20S108 signal was detected in up to 63.5% of cells in a bone marrow specimen 9 mo after hematopoietic stem cell transplantation. B, A single D20S108 signal was also detected in an aliquot of the hematopoietic stem cell collection
clones, 10 which is more frequent than in previously studied donor-derived CHIP. 14, 15 It is possible that del(20q) may have a more competitive advantage in hematopoietic stem cells than in CHIP, producing mature cells with del(20q) and contributing to clonal expansion.
Despite the clonal dominance of del(20q), the patient remains healthy without any evidence of myeloid neoplasm. The patient recovered to normal CBCs except for persistent thrombocytopenia.
We believe that the thrombocytopenia in our patient was due to delayed engraftment, considering the decreased number of megakaryocytes. The association of del(20q) with delayed engraftment of a megakaryocyte lineage needs to be determined through further studies. Although clinical progression to overt myeloid neoplasm was not evident in our patient, a study with a larger sample is needed to clearly define the fate of the del(20q) clone and to rule out the possibility of clonal evolution with additional mutation acquisition.
In summary, our case showed that del(20q), one of the most com- 
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